Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities.

Cureus · 2024 · PMC11330575 · PMID 39156992

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The data showed a trend toward improvement in migraine disability.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

While the mean difference in MIDAS scores favored the 140 mg dose by 6.39 points, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.